Related Experiment Videos
[Clinical study on cefdinir in pediatric field].
1Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital.
The Japanese Journal of Antibiotics
|August 1, 1990
Summary
Cefdinir (CFDN), an oral cephalosporin, demonstrated a 96% efficacy rate in treating pediatric infections with no significant side effects. Pharmacokinetic studies showed variable plasma levels and urinary recovery in children.
Area of Science:
- Pharmacology
- Pediatrics
- Infectious Diseases
Background:
- Cefdinir (CFDN) is a novel oral cephalosporin antibiotic.
- Understanding its pharmacokinetic and clinical profile is crucial for pediatric use.
Purpose of the Study:
- To evaluate the pharmacokinetics and clinical efficacy of cefdinir in pediatric patients.
- To assess the safety and tolerability of cefdinir in children.
Main Methods:
- Pharmacokinetic analysis in two pediatric patients administered 3 mg/kg of CFDN.
- Clinical efficacy assessment in 25 children with various infectious diseases.
- Monitoring of clinical laboratory tests for safety evaluation.
Main Results:
- Peak plasma concentrations of CFDN varied between patients.
- High clinical efficacy rate of 96% (24/25) and bacteriological eradication rate of 83.3% (10/12) were observed.
- No serious adverse events were reported; minor elevations in eosinophils and GPT were noted.
Conclusions:
- Cefdinir exhibits promising pharmacokinetic properties and high clinical effectiveness in pediatric infectious diseases.
- The safety profile of cefdinir in children appears favorable, with minimal laboratory abnormalities.